

A
CORNEA
TRABECULAR OUTFLOW
SCHLEMM'S CHANNEL
TRABECULAR MESHWORK
NORMAL OUTFLOW CHANNELS
ANTERIOR CHAMBER
IRIDOCORNEAL ANGLE
IRIS
CILIARY PROCESSES
POSTERIOR CHAMBER
LENS
B
IMPLANT
DILATED OUTFLOW CHANNELS
LENS

FIG. 1





COLLECTOR CHANNELS
AQUEOUS VEINS
SCHLEMM'S CANAL
SCHLEMM'S CANAL
COLLECTOR CHANNELS
IMPLANT

FIG. 2



A slit lamp photograph through a gonioscopy lens showing an intracameral bimatoprost implant adjacent to the trabecular meshwork in the dog eye.

FIG. 3



Dilated vessels (arrows) represent outflow vessels in a dog that received a high-release bimatoprost intracameral implant described in greater detail in Example 1

FIG. 4




Example 1, animal with an intracameral bimatoprost implant with a ~60% reduction in IOP from baseline sustained for at least 5 months
API
Control
Percent Change from Baseline
20.0
0.0
-20.0
-40.0
-60.0
-80.0
0
6hrs
1
2
3
7
28
42
63
84
98
112
140
154
Time (Days)

FIG. 5



Dilated vessels (arrows) represent outflow vessels in a dog that received a low-release bimatoprost intracameral implant described in greater detail in Example 2

FIG. 6

Animal with an intracameral bimatoprost implant with ~ 40% reduction in IOP from baseline sustained for at least 42 days. This case is described in greater detail in Example 2




FIG. 7




8933-054, 30-API, 45-R203s, 20-R202H, 5-PEG3350
8933-102, 30-API, 45-R203s, 10-RG752s,10-R202H, 5-PEG3350
Total Release (%)
Time (Days)
Implant formulation in vitro release rate used Example 1

FIG. 8



Implant formulation in vitro release rate used Example 2 (arrow)

FIG. 9



IOP: Dog 1, 2, 3 (1 implant)
API
Placebo
Percent Change from Baseline
0
-10
-20
-30
-40
-50
-60
0
2
7
14
21
28
42
Time (Days)

FIG. 10



Dog 4, 5, 6 (2 implants)
API
Placebo
Percent Change from Baseline
0
-10
-20
-30
-40
-50
-60
0
2
7
14
21
28
42
Time (Days)

FIG. 11